Reducing the burden of Herpes Zoster in Italy

References

• Marin M, Güris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella. Recommendations of the Advisory Committee on immunization practices (ACIP). MMWR Recomm Rep 2007; 56:RR-4 1 - 40; PMID: 17585291
   PubMedGoogle Scholar
• Grose C. Varicella vaccination of children in the United States: assessment after the first decade 1995-2005. J Clin Virol 2005; 33:89 - 95, discussion 96-8; http://dx.doi.org/10.1016/j.jcv.2005.02.003; PMID: 15911422
   PubMed Web of Science ®Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:RR-5 1 - 30, quiz CE2-4; PMID: 18528318
   PubMedGoogle Scholar
• Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007; 356:1338 - 43; http://dx.doi.org/10.1056/NEJMct066061; PMID: 17392303
   PubMed Web of Science ®Google Scholar
• Johnson RW, Wasner G, Saddier P, Baron R. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 2008; 25:991 - 1006; http://dx.doi.org/10.2165/0002512-200825120-00002; PMID: 19021299
   PubMed Web of Science ®Google Scholar
• Weaver BA. Herpes zoster overview: natural history and incidence. J Am Osteopath Assoc 2009; 109:Suppl 2 S2 - 6; PMID: 19553632
   PubMedGoogle Scholar
• Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc 2009; 109:Suppl 2 S13 - 7; PMID: 19553630
   PubMedGoogle Scholar
• Gabutti G, Serenelli C, Sarno O, Marconi S, Corazza M, Virgili A. Epidemiologic features of patients affected by herpes zoster: database analysis of the Ferrara University Dermatology Unit, Italy. Med Mal Infect 2010; 40:268 - 72; http://dx.doi.org/10.1016/j.medmal.2009.09.005; PMID: 19836913
   PubMed Web of Science ®Google Scholar
• Heininger U, Seward JF. Varicella. Lancet 2006; 368:1365 - 76; http://dx.doi.org/10.1016/S0140-6736(06)69561-5; PMID: 17046469
   PubMed Web of Science ®Google Scholar
• Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005; 352:2266 - 7; http://dx.doi.org/10.1056/NEJMp058091; PMID: 15930416
   PubMed Web of Science ®Google Scholar
• Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48:Suppl 1 S2 - 7; http://dx.doi.org/10.1016/S1386-6532(10)70002-0; PMID: 20510263
   PubMed Web of Science ®Google Scholar
• Sadaoka K, Okamoto S, Gomi Y, Tanimoto T, Ishikawa T, Yoshikawa T, Asano Y, Yamanishi K, Mori Y. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay. J Infect Dis 2008; 198:1327 - 33; http://dx.doi.org/10.1086/592219; PMID: 18774884
   PubMed Web of Science ®Google Scholar
• Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology 2013; 81:928 - 30; http://dx.doi.org/10.1212/WNL.0b013e3182a3516e; PMID: 23999562
   PubMed Web of Science ®Google Scholar
• Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev 2013; 26:728 - 43; http://dx.doi.org/10.1128/CMR.00052-13; PMID: 24092852
   PubMed Web of Science ®Google Scholar
• Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I, Rota MC, de Melker H, Mossong J, Slacikova M, et al. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 2007; 25:7866 - 72; http://dx.doi.org/10.1016/j.vaccine.2007.07.036; PMID: 17919788
   PubMed Web of Science ®Google Scholar
• Guido M, Tinelli A, De Donno A, Quattrocchi M, Malvasi A, Campilongo F, Zizza A, Seroepidemiology Group. Susceptibility to varicella-zoster among pregnant women in the province of Lecce, Italy. J Clin Virol 2012; 53:72 - 6; http://dx.doi.org/10.1016/j.jcv.2011.10.007; PMID: 22074933
   PubMedGoogle Scholar
• Viner K, Perella D, Lopez A, Bialek S, Newbern C, Pierre R, Spells N, Watson B. Transmission of varicella zoster virus from individuals with herpes zoster or varicella in school and day care settings. J Infect Dis 2012; 205:1336 - 41; http://dx.doi.org/10.1093/infdis/jis207; PMID: 22454467
   PubMedGoogle Scholar
• Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61:310 - 6; http://dx.doi.org/10.1097/00005792-198209000-00003; PMID: 6981045
   PubMed Web of Science ®Google Scholar
• Meister W, Neiss A, Gross G, Doerr H, Höbel W, Malin J, von Essen J, Reimann B, Witke C, Wutzler P. Demography, symptomatology, and course of disease in ambulatory zoster patients. A physician-based survey in Germany. Intervirology 1998; 41:272 - 7; http://dx.doi.org/10.1159/000024949; PMID: 10325537
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Breuer J, Dwyer DE, Gronow DW, Helme RD, Litt JC, Levin MJ, Macintyre CR. The prevention and management of herpes zoster. Med J Aust 2008; 188:171 - 6; PMID: 18241179
   PubMed Web of Science ®Google Scholar
• Choi WS. Herpes zoster vaccine in Korea. Clin Exp Vaccine Res 2013; 2:92 - 6; http://dx.doi.org/10.7774/cevr.2013.2.2.92; PMID: 23858399
   PubMedGoogle Scholar
• Volpi A, Gatti A, Pica F. Frequency of herpes zoster recurrence. Mayo Clin Proc 2011; 86:586 - , author reply 586-7; http://dx.doi.org/10.4065/mcp.2011.0096; PMID: 21628622
   PubMed Web of Science ®Google Scholar
• Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009; 84:274 - 80; http://dx.doi.org/10.4065/84.3.274; PMID: 19252116
   PubMed Web of Science ®Google Scholar
• Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines 2010; 9:Suppl 21 - 6; http://dx.doi.org/10.1586/erv.10.30; PMID: 20192714
   PubMed Web of Science ®Google Scholar
• Watson P. Postherpetic neuralgia. Am Fam Physician 2011; 84:690 - 2; PMID: 21916395
   PubMed Web of Science ®Google Scholar
• Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 2004; 4:26 - 33; http://dx.doi.org/10.1016/S1473-3099(03)00857-0; PMID: 14720565
   PubMed Web of Science ®Google Scholar
• Chen SY, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S, Levin MJ. Incidence of herpes zoster in patients with altered immune function. Infection 2014; 42:325 - 34; http://dx.doi.org/10.1007/s15010-013-0550-8; PMID: 24214127
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Volpi A, McKendrick M, Wijck Av, Oaklander AL. Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol 2010; 48:Suppl 1 S20 - 8; http://dx.doi.org/10.1016/S1386-6532(10)70005-6; PMID: 20510264
   PubMedGoogle Scholar
• Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013; 13:170; http://dx.doi.org/10.1186/1471-2334-13-170; PMID: 23574765
   PubMed Web of Science ®Google Scholar
• Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leplège A, El Hasnaoui A, de Labareyre C. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001; 33:62 - 9; http://dx.doi.org/10.1086/320884; PMID: 11389496
   PubMed Web of Science ®Google Scholar
• Heymann AD, Chodick G, Karpati T, Kamer L, Kremer E, Green MS, Kokia E, Shalev V. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection 2008; 36:226 - 30; http://dx.doi.org/10.1007/s15010-007-6347-x; PMID: 18454342
   PubMed Web of Science ®Google Scholar
• Okamoto S, Hata A, Sadaoka K, Yamanishi K, Mori Y. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis 2009; 200:1606 - 10; http://dx.doi.org/10.1086/644646; PMID: 19821719
   PubMed Web of Science ®Google Scholar
• Gialloreti LE, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, Serradell L, di Marzo R, Volpi A. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis 2010; 10:230; http://dx.doi.org/10.1186/1471-2334-10-230; PMID: 20682044
   PubMed Web of Science ®Google Scholar
• Franco E, Perinetti E, Marchettini P, et al. Proportion of Post-Herpetic Neuralgia among patients with Herpes Zoster in Italy - a multicenter prospective observational study (Heroes study). EUGMS Venice 2-4 Oct 2013, Poster session
   Google Scholar
• Gabutti G, Serenelli C, Cavallaro A, Ragni P. Herpes zoster associated hospital admissions in Italy: review of the hospital discharge forms. Int J Environ Res Public Health 2009; 6:2344 - 53; http://dx.doi.org/10.3390/ijerph6092344; PMID: 19826547
   PubMed Web of Science ®Google Scholar
• Kempf W, Meylan P, Gerber S, Aebi C, Agosti R, Büchner S, Coradi B, Garweg J, Hirsch H, Kind C, et al. Swiss recommendations for the management of varicella zoster virus infections. Swiss Med Wkly 2007; 137:239 - 51; PMID: 17557214
   PubMed Web of Science ®Google Scholar
• Song H, Lee J, Lee M, Choi WS, Choi JH, Lee MS, Hashemi M, Rampakakis E, Kawai K, White R, et al. Burden of illness, quality of life, and healthcare utilization among patients with herpes zoster in South Korea: a prospective clinical-epidemiological study. Int J Infect Dis 2014; 20:23 - 30; http://dx.doi.org/10.1016/j.ijid.2013.11.018; PMID: 24412314
   PubMed Web of Science ®Google Scholar
• Studahl M, Petzold M, Cassel T. Disease burden of herpes zoster in Sweden--predominance in the elderly and in women - a register based study. BMC Infect Dis 2013; 13:586; http://dx.doi.org/10.1186/1471-2334-13-586; PMID: 24330510
   PubMed Web of Science ®Google Scholar
• Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Z Gesundh Wiss 2012; 20:441 - 51; http://dx.doi.org/10.1007/s10389-011-0481-8; PMID: 22822293
   PubMedGoogle Scholar
• Breuer J, Pacou M, Gauthier A, Brown MM. Herpes zoster as a risk factor for stroke and TIA: a retrospective cohort study in the UK. Neurology 2014; 82:206 - 12; http://dx.doi.org/10.1212/WNL.0000000000000038; PMID: 24384645
   PubMed Web of Science ®Google Scholar
• Langan SM, Minassian C, Smeeth L, Thomas SL. Risk of stroke following herpes zoster: a self-controlled case-series study. Clin Infect Dis 2014; 58:1497 - 503; http://dx.doi.org/10.1093/cid/ciu098; PMID: 24700656
   PubMed Web of Science ®Google Scholar
• Kim SR, Khan F, Ramirez-Fort MK, Downing C, Tyring SK. Varicella zoster: an update on current treatment options and future perspectives. Expert Opin Pharmacother 2014; 15:61 - 71; http://dx.doi.org/10.1517/14656566.2014.860443; PMID: 24289750
   PubMed Web of Science ®Google Scholar
• Christo PJ, Hobelmann G, Maine DN. Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management. Drugs Aging 2007; 24:1 - 19; http://dx.doi.org/10.2165/00002512-200724010-00001; PMID: 17233544
   PubMedGoogle Scholar
• Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2014; 2:CD006866; http://dx.doi.org/10.1002/14651858.CD006866.pub3; PMID: 24500927
   PubMed Web of Science ®Google Scholar
• Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280:1837 - 42; http://dx.doi.org/10.1001/jama.280.21.1837; PMID: 9846778
   PubMed Web of Science ®Google Scholar
• Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32:1481 - 6; http://dx.doi.org/10.1086/320169; PMID: 11317250
   PubMed Web of Science ®Google Scholar
• Hempenstall K, Nurmikko TJ, Johnson RW, A’Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005; 2:e164; http://dx.doi.org/10.1371/journal.pmed.0020164; PMID: 16013891
   PubMed Web of Science ®Google Scholar
• Johnson RW. Zoster-associated pain: what is known, who is at risk and how can it be managed?. Herpes 2007; 14:Suppl 2 30 - 4; PMID: 17939893
   PubMedGoogle Scholar
• Johnson RW, McElhaney J. Postherpetic neuralgia in the elderly. Int J Clin Pract 2009; 63:1386 - 91; http://dx.doi.org/10.1111/j.1742-1241.2009.02089.x; PMID: 19691624
   PubMed Web of Science ®Google Scholar
• Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995; 45:Suppl 8 S41 - 6; http://dx.doi.org/10.1212/WNL.45.12_Suppl_8.S41; PMID: 8545018
   PubMed Web of Science ®Google Scholar
• Levin MJ, Barber D, Goldblatt E, Jones M, LaFleur B, Chan C, Stinson D, Zerbe GO, Hayward AR. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998; 178:Suppl 1 S109 - 12; http://dx.doi.org/10.1086/514264; PMID: 9852987
   PubMed Web of Science ®Google Scholar
• Trannoy E, Berger R, Holländer G, Bailleux F, Heimendinger P, Vuillier D, Creusvaux H. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000; 18:1700 - 6; http://dx.doi.org/10.1016/S0264-410X(99)00510-1; PMID: 10689152
   PubMed Web of Science ®Google Scholar
• Breuer J. Vaccination to prevent varicella and shingles. J Clin Pathol 2001; 54:743 - 7; http://dx.doi.org/10.1136/jcp.54.10.743; PMID: 11577118
   PubMed Web of Science ®Google Scholar
• Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003; 188:1336 - 44; http://dx.doi.org/10.1086/379048; PMID: 14593591
   PubMed Web of Science ®Google Scholar
• Herpes Zoster vaccine (live). Zostavax Summary of product characteristics 2013. revision 18 December 2013
   Google Scholar
• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al, Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271 - 84; http://dx.doi.org/10.1056/NEJMoa051016; PMID: 15930418
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Gnann JW Jr., McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922 - 8; http://dx.doi.org/10.1093/cid/cir970; PMID: 22291101
   PubMed Web of Science ®Google Scholar
• Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, et al, Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012; 55:1320 - 8; http://dx.doi.org/10.1093/cid/cis638; PMID: 22828595
   PubMed Web of Science ®Google Scholar
• Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305:160 - 6; http://dx.doi.org/10.1001/jama.2010.1983; PMID: 21224457
   PubMed Web of Science ®Google Scholar
• Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308:43 - 9; http://dx.doi.org/10.1001/jama.2012.7304; PMID: 22760290
   PubMed Web of Science ®Google Scholar
• Gagliardi AMZ, Gomez Liva BN, Torloni MR, Soares BGO. Vaccines for preventing Herpes Zoster in older adults (review). The Cochrane Library 2012;
   Google Scholar
• Murray AV, Reisinger KS, Kerzner B, Stek JE, Sausser TA, Xu J, Wang WW, Chan IS, Annunziato PW, Parrino J. Safety and tolerability of zoster vaccine in adults ≥60 years old. Hum Vaccin 2011; 7:1130 - 6; http://dx.doi.org/10.4161/hv.7.11.17982; PMID: 22048110
   PubMed Web of Science ®Google Scholar
• Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, Baggs J, Weinmann S, Baxter R, Nordin J, et al, Vaccine Safety Datalink (VSD) Team. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med 2012; 271:510 - 20; http://dx.doi.org/10.1111/j.1365-2796.2011.02474.x; PMID: 22026504
   PubMed Web of Science ®Google Scholar
• Baxter R, Tran TN, Hansen J, Emery M, Fireman B, Bartlett J, Lewis N, Saddier P. Safety of Zostavax™--a cohort study in a managed care organization. Vaccine 2012; 30:6636 - 41; http://dx.doi.org/10.1016/j.vaccine.2012.08.070; PMID: 22963800
   PubMed Web of Science ®Google Scholar
• Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, Stek JE, Schlienger K, Chan IS, Silber JL. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine 2010; 28:4204 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.04.003; PMID: 20416263
   PubMed Web of Science ®Google Scholar
• EUnetHTA. Zostavax for the prevention of Herpes Zoster and Post-Herpetic Neuralgia. Pilot assessment using the draft HTA Core Model for rapid relative effectiveness assessment. September 2013; http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Zostavax_main%20report%20including%20appendices_20130922.pdf (last access April 2014)
   Google Scholar
• Bresse X, Annemans L, Préaud E, Bloch K, Duru G, Gauthier A. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2013; 13:393 - 406; http://dx.doi.org/10.1586/erp.13.19; PMID: 23537397
   PubMed Web of Science ®Google Scholar
• Ruggeri M. Analisi di costo-efficacia del vaccino contro l'Herpes Zoster e la nevralgia posterpetica in Italia. 6° Congresso Nazionale SIHTA. Bari 7-9 Novembre 2013
   Google Scholar